8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report:  June 10, 2005

(Date of earliest event reported)

ABIOMED, Inc.

(Exact name of registrant as specified in its charter)

Delaware	04-2743260
(State or Other Jurisdiction of Incorporation)	(IRS Employer Identification Number)
0-20584
(Commission File Number)
22 Cherry Hill Drive Danvers, MA 01923
(Address of Principal Executive Offices, including Zip Code)
(978) 777-5410
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02Departure of Directors or Principal Officers; Election of Directors Appointment of Principal Officers

On June 10, 2005, David M. Lederman, Ph.D. resigned as Chairman of the Board of Directors and as a Director of ABIOMED, Inc.  On June 15, 2005, we issued a press release announcing the resignation of Dr. Lederman and also announcing that Michael R. Minogue, President and Chief Executive Officer, will assume the additional role of Chairman of the Board of Directors. The full text of the press release is attached as exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01Financial Statements and Exhibits

(c) Exhibits

Exhibit Number	Description
99.1	Press release dated June 15, 2005

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ABIOMED, Inc.
	By:	/s/ Charles B. Haaser
		Charles B. Haaser
		Controller
		Principal Accounting Officer
		Principal Financial Officer
Date: June 15, 2005

3

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release dated June 15, 2005

4

EX-99.1

Exhibit 99.1

ABIOMED Elects Michael R. Minogue Chairman of the Board of Directors

DANVERS, Mass., June 15 — ABIOMED, Inc. (NASDAQ: ABMD) announced today that Michael R. Minogue, President and Chief Executive Officer, has assumed the additional position of Chairman of the Board of Directors.

ABIOMED also announced today that David M. Lederman has resigned as Chairman of the Board of Directors and as a Director of ABIOMED.

David Lederman was the founder of ABIOMED. He created the Company over 20 years ago to fulfill his dream of developing a totally implantable artificial heart. Under his direction, ABIOMED developed the AbioCor, the world’s first battery-powered fully implantable replacement heart system, and other advanced medical products which have provided short and long term support for thousands of cardiac patients.

“David’s passion and commitment to patients is a legacy that will continue to inspire ABIOMED employees. It is an honor and privilege to follow him as Chairman of the company,” commented Minogue. ABIOMED has named its employee award and recognition program after Dr. Lederman.

About ABIOMED

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED, which currently sells the BVS® 5000 Biventricular Support System and the AB5000(TM) Circulatory Support System, is the market leader in devices for the temporary support of patients with failing but potentially recoverable hearts. In September 2004, ABIOMED applied for initial FDA market approval for the AbioCor® Implantable Replacement Heart to treat a defined subset of irreversible end-stage heart failure patients under a Humanitarian Device Exemption.

This Release contains forward-looking statements, including statements regarding development of ABIOMED’s existing and new products, the Company’s progress toward commercial growth, and future opportunities. The Company’s actual results may differ materially from those anticipated in these forward- looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Investor and Media Relations:

Javier Jimenez

VP Operations

(978) 646-1411 ir@abiomed.com

(978) 646-1419 mediarelations@abiomed.com